Improved drug targeting of cancer cells by utilizing actively targetable folic acid-conjugated albumin nanospheres.
Shen
Zheyu
Z
School of Chemical Engineering, The University of Adelaide, Adelaide, SA 5005, Australia. shenzy@ymail.com
Li
Yan
Y
Kohama
Kazuhiro
K
Oneill
Brian
B
Bi
Jingxiu
J
D000903:Antibiotics, Antineoplastic / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D001692:Biological Transport; D002470:Cell Survival / Q000187:drug effects; D002626:Chemistry, Pharmaceutical; D004317:Doxorubicin / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D004337:Drug Carriers; D004339:Drug Compounding; D005260:Female; D058975:Folate Receptor 1 / Q000378:metabolism; D005492:Folic Acid / Q000031:analogs & derivatives / Q000737:chemistry / Q000378:metabolism*; D006367:HeLa Cells; D006801:Humans; D008027:Light; D046529:Microscopy, Electron, Transmission; D054118:Nanospheres; D010316:Particle Size; D012542:Scattering, Radiation; D012710:Serum Albumin, Bovine / Q000737:chemistry / Q000378:metabolism*; D012995:Solubility; D013499:Surface Properties; D013997:Time Factors; D002583:Uterine Cervical Neoplasms / Q000378:metabolism / Q000473:pathology*
D000903:Antibiotics, Antineoplastic; D004337:Drug Carriers; C548696:FOLR1 protein, human; D058975:Folate Receptor 1; D012710:Serum Albumin, Bovine; D004317:Doxorubicin; D005492:Folic Acid